Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF



Status:Recruiting
Conditions:High Blood Pressure (Hypertension), High Blood Pressure (Hypertension), Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:3/8/2019
Start Date:November 14, 2018
End Date:December 2019
Contact:Kevin Crawford
Email:k.crawford@tenaxthera.com
Phone:919-855-2145

Use our guide to learn which trials are right for you!

A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction (PH-HFpEF)

Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with
placebo in hemodynamic improvement with exercise in PH-HFpEF subjects

Levosimendan and its prolonged active metabolite, OR-1896, have been shown to have favorable
hemodynamic effects in subjects with pulmonary hypertension and right heart failure. Clinical
studies that have been conducted in subjects with right heart failure and pulmonary
hypertension suggest levosimendan may be an effective therapy in treatment of subjects with
PH-HFpEF. This study will provide demonstration of levosimendan/OR-1896's effectiveness in
critical measures of hemodynamic response in weekly administration of levosimendan and the
concomitant response as measured by exercise capacity, subject quality of life, and changes
in functional capacity. These data will support and guide the Phase 3 development of
levosimendan in PH-HFpEF subjects.

Inclusion Criteria:

Criteria to enter Open-label, Lead-in Dose Phase:

- Diagnosis of WHO Group 2 Pulmonary Hypertension (PH) with heart failure and preserved
ejection fraction (HFpEF) confirmed at the time of the diagnosis of pulmonary
hypertension.

- Baseline Pulmonary Arterial Pressure (PAP) ≥35, PCWP ≥20, NYHA Class IIb/III, Left
Ventricular Ejection Fraction (LVEF) ≥40%

- Ability to walk at least 100 meters, but not more than 400 meters in a six-minute walk
test.

- Stable oxygen treatment (if applicable), and medications for heart failure and
respiratory condition

Criterion for Randomization to Double-blind Phase:

- Response to Open-label, Lead-in Levosimendan: Patients who demonstrate a ≥4mmHg
reduction in PCWP from baseline measured at bicycle exercise (25 watts) with no more
than a 10% decrease from baseline in cardiac index

Exclusion Criteria:

- Subject has primary diagnosis of PH other than Group 2 PH-HFpEF

- Previous Percutaneous Coronary Intervention (PCI) or cardiac surgery or symptomatic
valve disease, unless they have a negative stress test in last 12 months)

- Congenital heart disease

- Clinically significant lung disease

- Planned heart or lung surgery

- Cardiac Index >4.0 L/min/m2

- Concomitant administration of pulmonary vasodilator therapy or taken within 14 days

- Dialysis or Glomerular Filtration Rate (GFR) <30 mL/min/1.73 m2

- Liver dysfunction with Child Pugh Class B or C

- Evidence of systemic infection

- Weight > 135kg

- Symptomatic systolic blood pressure (SBP) cannot be managed to ensure SBP >100 mmHg

- Heart rate >= 100 bpm with study drug, symptomatic and persistent for at least 10
minutes

- Hemoglobin < 80 g/L

- Serum potassium < 3.0 mmol/L or > 5.5 mmol/L at baseline

- Patients having severely compromised immune function

- Pregnant, suspected to be pregnant, or breast-feeding
We found this trial at
6
sites
3400 Spruce St
Philadelphia, Pennsylvania 19104
 (215) 662-4000
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
300 Community Drive
Manhasset, New York 11030
(516) 562-0100
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
?
mi
from
Manhasset, NY
Click here to add this to my saved trials
251 E Huron St
Chicago, Illinois 60611
(312) 926-2000
Northwestern Memorial Hospital Northwestern Memorial is an academic medical center hospital where the patient comes...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rochester, New York 55905
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Stanford, California 94305
?
mi
from
Stanford, CA
Click here to add this to my saved trials